Professor Ilaria Bellantuono
MD, PhD
School of Medicine and Population Health
Professor of Musculoskeletal Ageing
Co-Director, The Healthy Lifespan Institute
+44 114 215 9037
Full contact details
School of Medicine and Population Health
DU33, D Floor
The Medical School
Beech Hill Road
Sheffield
S10 2RX
- Profile
-
For enquiries please contact - SMPH-West-Operational@sheffield.ac.uk
I am Professor of Musculoskeletal Ageing and Co-Director of the Healthy Lifespan Institute (HELSI) at the University of Sheffield. I am the co-founder and Co-lead of UKAgeNet.
I am a medically trained scientist focused on understanding the biology of ageing and identifying strategies to prevent multimorbidity and frailty through geroprotective interventions. My scientific journey began in stem cell biology, with a PhD in gene therapy for inherited blood disorders at the University of Manchester and postdoctoral work on leukemic and mesenchymal stem cells. This early work continues to shape how I approach the challenges of ageing today.
Current PhD Opportunities:
- Research interests
-
My research aims to delay or prevent the onset of multiple age-related diseases and frailty by targeting the biological processes of ageing itself, using medicinal drugs known as geroprotectors. I focus on generating robust preclinical data in mouse models to support the transition to phase 1 clinical trials aimed at preventing frailty. This includes identifying individuals at risk of frailty and addressing the regulatory challenges involved in advancing these therapies to clinical application.
I work closely with colleagues and experts across various age-related diseases to uncover common mechanisms of ageing—such as DNA repair deficiencies and cellular senescence—that drive multiple long-term chronic conditions. Together, we investigate how diseases cluster, identify compounds that target shared mechanisms, and explore their potential to impact multiple conditions simultaneously. I am also involved in designing clinical trials tailored to these approaches.
In collaboration with industrial partners and regulatory experts, I have contributed to reaching a European-level consensus on the best strategies to bring geroprotectors to the clinic. Our roadmap for achieving this is outlined in: Bellantuono I. Find drugs that delay many diseases of old age. Nature. 2018.
My contribution to the field of ageing has been recognised with the Dunhill Medical Trust Excellence in Leadership Award (Senior), 2024.
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- Insights into relationship of environmental inequalities and multimorbidity: a population-based study. Environmental Health, 23. View this article in WRRO
- Aging, Parkinson’s disease, and models: what are the challenges?. Aging Biology, 1, 1-30. View this article in WRRO
- A p21‐GFP zebrafish model of senescence for rapid testing of senolytics in vivo. Aging Cell, 22(6). View this article in WRRO
- The use of geroprotectors to prevent multimorbidity: Opportunities and challenges. Mechanisms of Ageing and Development, 193, 111391-111391.
- Tackling immunosenescence to improve COVID-19 outcomes and vaccine response in older adults. The Lancet Healthy Longevity, 1(2), e55-e57.
- A toolbox for the longitudinal assessment of healthspan in aging mice. Nature Protocols, 15(2), 540-574. View this article in WRRO
- Geroprotectors: A role in the treatment of frailty. Mechanisms of Ageing and Development, 180, 11-20.
- Modelling physical resilience in ageing mice. Mechanisms of Ageing and Development, 177, 91-102. View this article in WRRO
- Find drugs that delay many diseases of old age. Nature, 554(7692), 293-295.
- The chondrocyte clock gene Bmal1 controls cartilage homeostasis and integrity. Journal of Clinical Investigation, 126(1), 365-376.
- Zoledronate Attenuates Accumulation of DNA Damage in Mesenchymal Stem Cells and Protects Their Function. Stem Cells. View this article in WRRO
All publications
Journal articles
- A geroscience response to cancellation of the UK’s Medicines Repurposing Programme: challenges and opportunities. The Lancet Healthy Longevity, 6(8), 100744-100744.
- Senescence cell induction methods display diverse metabolic reprogramming and reveal an underpinning serine/taurine reductive metabolic phenotype.. Aging cell. View this article in WRRO
- Protocol for assessing the structural architecture, integrity, and cellular composition of murine bone ex vivo. STAR Protocols, 6(2), 103843-103843.
- Defining an ageing-related pathology, disease or syndrome: international consensus statement. GeroScience, 47(2), 1713-1720. View this article in WRRO
- Insights into relationship of environmental inequalities and multimorbidity: a population-based study. Environmental Health, 23. View this article in WRRO
- Type-H endothelial cell protein Clec14a orchestrates osteoblast activity during trabecular bone formation and patterning. Communications Biology, 7(1). View this article in WRRO
- Extra-osseous roles of the RANK-RANKL-OPG axis with a focus on skeletal muscle. Current Osteoporosis Reports, 22(6), 632-650. View this article in WRRO
- The loading direction dramatically affects the mechanical properties of the mouse tibia. Frontiers in Bioengineering and Biotechnology, 12. View this article in WRRO
- Correction to “A
p21‐GFP zebrafish model of senescence for rapid testing of senolytics in vivo”. Aging Cell, 23(3).
- Aging, Parkinson’s disease, and models: what are the challenges?. Aging Biology, 1, 1-30. View this article in WRRO
- A p21‐GFP zebrafish model of senescence for rapid testing of senolytics in vivo. Aging Cell, 22(6). View this article in WRRO
- Accuracy of in vivo microCT imaging in assessing the microstructural properties of the mouse tibia subchondral bone. Frontiers in Endocrinology, 13. View this article in WRRO
- The kinesin gene KIF26B modulates the severity of post-traumatic heterotopic ossification. International Journal of Molecular Sciences, 23(16). View this article in WRRO
- Reproducibility of densitometric and biomechanical assessment of the mouse tibia from in vivo micro-CT images. Frontiers in Endocrinology, 13.
- Geroprotectors and skeletal health : beyond the headlines. Frontiers in Cell and Developmental Biology, 10. View this article in WRRO
- Zoledronate extends health span and survival via the mevalonate pathway in a FOXO-dependent manner. The Journals of Gerontology: Series A, 77(8), 1494-1502. View this article in WRRO
- miR‐24 and its target gene Prdx6 regulate viability and senescence of myogenic progenitors during aging. Aging Cell, 20(10). View this article in WRRO
- What researchers on ageing should know about multimorbidity, geroprotectors and artificial intelligence. Mechanisms of Ageing and Development, 195, 111453-111453.
- Non-invasive prediction of the mouse tibia mechanical properties from microCT images: comparison between different finite element models. Biomechanics and Modeling in Mechanobiology, 20(3), 941-955. View this article in WRRO
- miR-24:Prdx6 interactions regulate oxidative stress and viability of myogenic progenitors during ageing.
- The use of geroprotectors to prevent multimorbidity: Opportunities and challenges. Mechanisms of Ageing and Development, 193, 111391-111391.
- Optimization of the failure criterion in micro-Finite Element models of the mouse tibia for the non-invasive prediction of its failure load in preclinical applications. Journal of the Mechanical Behavior of Biomedical Materials, 113. View this article in WRRO
- Tackling immunosenescence to improve COVID-19 outcomes and vaccine response in older adults. The Lancet Healthy Longevity, 1(2), e55-e57.
- Senescence and cancer : a review of clinical implications of senescence and senotherapies. Cancers, 12(8). View this article in WRRO
- Zoledronate extends healthspan and survival via the mevalonate pathway in a FOXO-dependent manner.
- A toolbox for the longitudinal assessment of healthspan in aging mice. Nature Protocols, 15(2), 540-574. View this article in WRRO
- Genome-wide association and functional analyses identify CASC20 and KIF26B as target loci in heterotopic ossification.
- Geroprotectors: A role in the treatment of frailty. Mechanisms of Ageing and Development, 180, 11-20.
- Modelling physical resilience in ageing mice. Mechanisms of Ageing and Development, 177, 91-102. View this article in WRRO
- ZOLEDRONATE EXTENDS LIFESPAN AND HEALTHSPAN IN VIVO. Innovation in Aging, 2(suppl_1), 545-545.
- An N -ethyl- N -nitrosourea (ENU) mutagenized mouse model for autosomal dominant non-syndromic kyphoscoliosis due to vertebral fusion. JBMR Plus, 2(3), 154-163. View this article in WRRO
- Find drugs that delay many diseases of old age. Nature, 554(7692), 293-295.
- Longitudinal effects of Parathyroid Hormone treatment on morphological, densitometric and mechanical properties of mouse tibia. Journal of the Mechanical Behavior of Biomedical Materials, 75, 244-251. View this article in WRRO
- Does age matter? The impact of rodent age on study outcomes. Laboratory Animals, 51(2), 160-169. View this article in WRRO
- Modelling ageing and age-related disease. Drug Discovery Today: Disease Models, 20, 27-32. View this article in WRRO
- MouseAge: Leading the way in the development of geroprotectors in Europe. Mechanisms of Ageing and Development, 160, 32-33.
- Interventions for age-related diseases: shifting the paradigm.. Mechanisms of Ageing and Development , 160, 69-92. View this article in WRRO
- Building for the future: essential infrastructure for rodent ageing studies. Mammalian Genome, 27(7-8), 440-444. View this article in WRRO
- Development of a protocol to quantify local bone adaptation over space and time: quantification of reproducibility. Journal of Biomechanics, 49(10), 2095-2099. View this article in WRRO
- The chondrocyte clock gene Bmal1 controls cartilage homeostasis and integrity. Journal of Clinical Investigation, 126(1), 365-376.
- Zoledronate Attenuates Accumulation of DNA Damage in Mesenchymal Stem Cells and Protects Their Function. Stem Cells. View this article in WRRO
- Evaluation of in-vivo measurement errors associated with micro-computed tomography scans by means of the bone surface distance approach.. Medical Engineering and Physics. View this article in WRRO
- Musculoskeletal changes in superoxide dismutase 1 null mice (1153.5). The FASEB Journal, 28(S1).
- Intra-femoral injection of human mesenchymal stem cells. Methods in Molecular Biology, 976, 131-141.
- Shared Ageing Research Models (ShARM): a new facility to support ageing research.. Biogerontology, 14(6), 789-794.
- Autosomal dominant hypercalciuria in a mouse model due to a mutation of the epithelial calcium channel, TRPV5.. PLoS One, 8(1), e55412.
- Intra-femoral injection of human mesenchymal stem cells.. Methods Mol Biol, 976, 131-141.
- Inner ear progenitor cells can be generated in vitro from human bone marrow mesenchymal stem cells.. Regen Med, 7(6), 757-767.
- A small molecule modulator of prion protein increases human mesenchymal stem cell lifespan, ex vivo expansion, and engraftment to bone marrow in NOD/SCID mice.. Stem Cells, 30(6), 1134-1143.
- Progeroid syndromes: models for stem cell aging?. Biogerontology, 13(1), 63-75.
- Glycogen synthase kinase-3α/β inhibition promotes in vivo amplification of endogenous mesenchymal progenitors with osteogenic and adipogenic potential and their differentiation to the osteogenic lineage.. J Bone Miner Res, 26(4), 811-821.
- Alterations in the self-renewal and differentiation ability of bone marrow mesenchymal stem cells in a mouse model of rheumatoid arthritis.. Arthritis Res Ther, 12(4), R149.
- A systems biology approach to Down syndrome: identification of Notch/Wnt dysregulation in a model of stem cells aging.. Biochim Biophys Acta, 1792(4), 353-363.
- Aging of marrow stromal (skeletal) stem cells and their contribution to age-related bone loss.. Biochim Biophys Acta, 1792(4), 364-370.
- Telomere length dynamics differ in foetal and early post-natal human leukocytes in a longitudinal study.. Biogerontology, 10(3), 279-284.
- Retrovirally-mediated genetic correction of mesenchymal stem cells from patients affected by mucopolysaccharidosis type II (Hunter Syndrome). GENE THER MOL BIOL, 12B, 167-174.
- Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS.. Mol Ther, 16(12), 2002-2010.
- Stem cell ageing: does it happen and can we intervene?. Expert Rev Mol Med, 9(31), 1-20.
- Hematopoietic progenitor cell deficiency in fetuses and children affected by Down's syndrome.. Exp Hematol, 34(12), 1611-1615.
- Detection of Wilms' tumor antigen--specific CTL in tumor-draining lymph nodes of patients with early breast cancer.. Clin Cancer Res, 12(1), 34-42.
- Marrow stromal cells from patients affected by MPS I differentially support haematopoietic progenitor cell development.. J Inherit Metab Dis, 28(6), 1045-1053.
- Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion.. Stem Cells, 22(5), 675-682.
- A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow.. Blood, 104(9), 2643-2645.
- Haemopoietic stem cells.. Int J Biochem Cell Biol, 36(4), 607-620.
- Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration.. Blood, 101(9), 3560-3567.
- High transduction efficiency of circulating first trimester fetal mesenchymal stem cells: potential targets for in utero ex vivo gene therapy.. BJOG, 109(8), 952-954.
- Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL.. Blood, 100(10), 3835-3837.
- High transduction efficiency of circulating first trimester fetal mesenchymal stem cells: potential targets for in utero ex vivo gene therapy. BJOG: An International Journal of Obstetrics and Gynaecology, 109(8), 952-954.
- Retrovirally mediated correction of bone marrow-derived mesenchymal stem cells from patients with mucopolysaccharidosis type I.. Blood, 99(5), 1857-1859.
- Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow.. Blood, 98(8), 2396-2402.
- Immunoresponse to Wilms Tumor antigen-1 (WT-1) in CML patients.. BLOOD, 96(11), 144A-144A.
- Identification of mesenchymal stem cells in human first trimester fetal blood, liver and bone marrow.. BLOOD, 96(11), 279A-279A.
- The expression of full length Gp91-phox protein is associated with reduced amphotropic retroviral production.. Haematologica, 85(5), 451-457.
- Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood, 95(7), 2198-2203.
- Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1.. Blood, 95(7), 2198-2203.
- Selective elimination of leukemic progenitors by allorestricted CTL specific for Wilms tumor antigen-1 (WT-1).. BLOOD, 94(10), 532A-533A.
- Towards gene therapy of Hurler syndrome.. Cas Lek Cesk, 136(1), 27-31.
- Long-term in vitro correction of alpha-L-iduronidase deficiency (Hurler syndrome) in human bone marrow.. Proc Natl Acad Sci U S A, 93(5), 2025-2030.
- TREATMENT OF HIGH-RISK LEUKEMIA WITH BUSULFAN, CYCLOPHOSPHAMIDE, ETOPOSIDE AND ALLOGENEIC BONE-MARROW TRANSPLANTATION. EXP HEMATOL, 21(8), 1132-1132.
- GROWTH OF HEMATOPOIETIC PROGENITOR CELLS DERIVED FROM UMBILICAL-CORD BLOOD. EXP HEMATOL, 21(8), 1137-1137.
Book chapters
- Intestinal Stem Cells and the Development of Colorectal Neoplasia, Tissue Stem Cells (pp. 245-286). CRC Press
- Peripheral tolerance: the transplantation model Bernd M Spriewald and Kathryn J Wood, Infection and Immunity (pp. 95-118). CRC Press
Conference proceedings
- Degree of frailty impacts treatment & outcomes of breast cancer. FUTURE ONCOLOGY, Vol. 20 (pp 11-12)
- Correlating frailty & senescence: a biomarker study. FUTURE ONCOLOGY, Vol. 20 (pp 17-18)
- Abstract # 3231 Telomerase-dependent senescence and inflammation with ageing in the zebrafish brain. Brain, Behavior, and Immunity, Vol. 81(Supplement) (pp 7). Berlin, Germany, 4 June 2019 - 4 June 2019. View this article in WRRO
- Can Bisphosphonates extend Life Span? Effects on Stem Cell survival, DNA Repair and Tissue Regeneration. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 28
- TIBIAL PLATEAU BONE SURFACE ROUGHNESS - A POTENTIAL NEW EARLY MARKER TO DETECT ARTHRITIS?. OSTEOPOROSIS INTERNATIONAL, Vol. 23 (pp S574-S574)
- A system biology approach to Down Syndrome: identification of Notch/Wnt dysregulation in stem cells with age. JOURNAL OF MEDICAL GENETICS, Vol. 46 (pp S22-S22)
- Intramuscular delivery of GDNF with human mesenchymal stem cells protects dying motor neurons and prolongs survival in a rat model of familial ALS. CELL TRANSPLANTATION, Vol. 17(4) (pp 482-483)
- Human fetal haematopoietic stem cells show different telomere length dynamics from age-matched post natal stem cells in a longitudinal study. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 129 (pp 8-8)
- Human fetal hematopoietic stem cells show different telomere length dynamics to post natal and adult blood cells in a longitudinal study.. BLOOD, Vol. 102(11) (pp 566A-566A)
Datasets
- Data for the paper: "Optimization of the failure criterion in micro-Finite Element models of the mouse tibia for the non-invasive prediction of its failure load in preclinical applications".
Preprints
- Defining an Ageing-Related Pathology, Disease or Syndrome: International Consensus Statement, Cold Spring Harbor Laboratory.
- A p21-GFP zebrafish model of senescence for rapid testing of senolyticsin vivo, Cold Spring Harbor Laboratory.
- Insights into relationship of environmental inequalities and multimorbidity: a population-based study. Environmental Health, 23. View this article in WRRO
- Research group
-
PhD Students
- Olivia Turner
- Ziqian Sun
- Josie Cadman
- Nikita Soni
- Teaching interests
-
I am the Director of training for the HELSI-Dunhill Medical Trust Doctoral training program whose aims align with the HELSI mission of developing solutions for the prevention of multiple long-term chronic conditions and frailty.
Until 2017 I was the Director of training for the MRC-AR UK Centre for Integrated research into Musculoskeletal Ageing (CIMA). The Centre is a is a collaboration between the Universities of Liverpool, Newcastle and Sheffield and the training includes an MRes and PhD programme.
I also contribute to the Student Selected Components of Phase 1a of the MBChB course.
- Professional activities and memberships
-
Most of my time is now taken by the running of the Healthy Lifespan Institute and UKAgeNet. This has been built from my experience when I have Chaired and led the effort of the COST Action MouseAGE a European network comprising over 200 researchers from 25 EU countries to identify a roadmap to take medicinal drugs targeting mechanisms of ageing (geroprotectors) to the patients.
Previously I headed the Mellanby Centre skelet.AL laboratories (former Bone Analysis Laboratory), which provides access and expertise to contemporary technologies for the analysis of bone to investigators, internally and externally.
I was also the Director of Research for the Department of Oncology and Metabolism and a member of the Faculty Research and Innovation Committee, which oversees the Faculty strategic approach to Research and Innovation. At present I am serving as a panel member for the UKRI Future Leader Fellowship scheme.
I have been the Chair of the BBSRC Bioscience Skills and Careers (BSC) Strategy Advisory Panel, The BBSRC Fellowship portfolio monitoring group and a member of BBSRC Research Advisory Panel, roles I have enjoyed enormously and from which I have gained experience in policymaking in the vital skills and science sector.
I have taken part in evaluation of funding including NC3Rs, Arthritis Research UK and Horizon 2020 panels.